Patrizia Querzoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Patrizia Querzoli has a total of 384 co-authors. Here are the top co-authors by number of shared publications:
- Massimo Pedriali
Section of Anatomy, Histology and Pathological Cytology, University of Ferrara, Ferrara, Italy
37 shared publications - Saverio Alberti
Unit of Medical Genetics, Department of Biomedical Sciences—BIOMORF, University of Messina, Messina, Italy
28 shared publications - Rossano Lattanzio
Department of Innovative Technologies in Medicine & Dentistry, Center for Advanced Studies and Technology (CAST), ‘G. d’Annunzio’ University of Chieti–Pescara, Chieti, Italy
23 shared publications - Marco Trerotola
Laboratory of Cancer Pathology, Center for Advanced Studies and Technology (CAST), “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy
20 shared publications - Nicola Tinari
Department of Medical, Oral and Biotechnological Sciences, “G.d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy
20 shared publications - Pasquale Simeone
Center for Advanced Studies and Technology (CAST), “G.d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy
20 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Movie S1 from 3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability
Movie S1 from 3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S1 from 3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability
Movie S1 from 3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Movie S1 from 3D-informed targeting of the Trop-2 signal-activation site drives selective cancer vulnerability
Movie S1 from 3D-informed targeting of the Trop-2 signal-activation site drives selective cancer vulnerability
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S1 from 3D-informed targeting of the Trop-2 signal-activation site drives selective cancer vulnerability
Movie S1 from 3D-informed targeting of the Trop-2 signal-activation site drives selective cancer vulnerability
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from 3D-informed targeting of the Trop-2 signal-activation site drives selective cancer vulnerability
Next-generation Trop-2-targeted therapy against advanced cancers is hampered by expression of Trop-2 in normal tissues. We discovered that Trop-2 undergoes proteolytic activation by ADAM10 in cancer cells, leading to the exposure of a previously inaccessible protein groove flanked by two N-glycosylation sites. We designed a recognition strategy for this region, to drive selective cancer vulnerability in patients. Most undiscriminating anti-Trop-2 monoclonal antibodies (mAb) recognize a single immunodominant epitope. Hence, we removed it by deletion-mutagenesis. Cancer-specific, glycosylation-prone mAb were selected by ELISA, bio-layer interferometry, flow cytometry, confocal microscopy for differential binding to cleaved/activated, wild-type and glycosylation-site-mutagenized Trop-2. The resulting 2G10 mAb family binds Trop-2-expressing cancer cells, but not Trop-2 on normal cells. We humanized 2G10 by state-of-the-art CDR grafting/re-modeling, yielding Hu2G10. This antibody binds cancer-specific, cleaved/activated Trop-2 with Kd <10-12 M, and uncleaved/wtTrop-2 in normal cells with Kd 3.16x10-8 M, thus promising an unprecedented therapeutic index in patients. In vivo, Hu2G10 ablates growth of Trop-2-expressing breast, colon, prostate cancers, but shows no evidence of systemic toxicity, paving the way for a paradigm shift in Trop-2-targeted therapy.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from 3D-informed targeting of the Trop-2 signal-activation site drives selective cancer vulnerability
Next-generation Trop-2-targeted therapy against advanced cancers is hampered by expression of Trop-2 in normal tissues. We discovered that Trop-2 undergoes proteolytic activation by ADAM10 in cancer cells, leading to the exposure of a previously inaccessible protein groove flanked by two N-glycosylation sites. We designed a recognition strategy for this region, to drive selective cancer vulnerability in patients. Most undiscriminating anti-Trop-2 monoclonal antibodies (mAb) recognize a single immunodominant epitope. Hence, we removed it by deletion-mutagenesis. Cancer-specific, glycosylation-prone mAb were selected by ELISA, bio-layer interferometry, flow cytometry, confocal microscopy for differential binding to cleaved/activated, wild-type and glycosylation-site-mutagenized Trop-2. The resulting 2G10 mAb family binds Trop-2-expressing cancer cells, but not Trop-2 on normal cells. We humanized 2G10 by state-of-the-art CDR grafting/re-modeling, yielding Hu2G10. This antibody binds cancer-specific, cleaved/activated Trop-2 with Kd <10-12 M, and uncleaved/wtTrop-2 in normal cells with Kd 3.16x10-8 M, thus promising an unprecedented therapeutic index in patients. In vivo, Hu2G10 ablates growth of Trop-2-expressing breast, colon, prostate cancers, but shows no evidence of systemic toxicity, paving the way for a paradigm shift in Trop-2-targeted therapy.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Movie S1 from 3D-informed targeting of the Trop-2 signal-activation site drives selective cancer vulnerability
Movie S1 from 3D-informed targeting of the Trop-2 signal-activation site drives selective cancer vulnerability
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S1 from 3D-informed targeting of the Trop-2 signal-activation site drives selective cancer vulnerability
Movie S1 from 3D-informed targeting of the Trop-2 signal-activation site drives selective cancer vulnerability
- Open Access
- 1 June 2023
- Published by American Association for Cancer Research (AACR)
Movie S1 from 3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability
Movie S1 from 3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability
- 1 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S1 from 3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability
Movie S1 from 3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability
- Open Access
- 1 June 2023
- Published by American Association for Cancer Research (AACR)
Movie S1 from 3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability
Movie S1 from 3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability
- 1 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S1 from 3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability
Movie S1 from 3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability
- Open Access
- 1 June 2023
- Published by American Association for Cancer Research (AACR)
Data from 3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability
Next-generation Trop-2–targeted therapy against advanced cancers is hampered by expression of Trop-2 in normal tissues. We discovered that Trop-2 undergoes proteolytic activation by ADAM10 in cancer cells, leading to the exposure of a previously inaccessible protein groove flanked by two N-glycosylation sites. We designed a recognition strategy for this region, to drive selective cancer vulnerability in patients. Most undiscriminating anti–Trop-2 mAbs recognize a single immunodominant epitope. Hence, we removed it by deletion mutagenesis. Cancer-specific, glycosylation-prone mAbs were selected by ELISA, bio-layer interferometry, flow cytometry, confocal microscopy for differential binding to cleaved/activated, wild-type and glycosylation site–mutagenized Trop-2. The resulting 2G10 mAb family binds Trop-2–expressing cancer cells, but not Trop-2 on normal cells. We humanized 2G10 by state-of-the-art complementarity determining region grafting/re-modeling, yielding Hu2G10. This antibody binds cancer-specific, cleaved/activated Trop-2 with Kd < 10−12 mol/L, and uncleaved/wtTrop-2 in normal cells with Kd 3.16×10−8 mol/L, thus promising an unprecedented therapeutic index in patients. In vivo, Hu2G10 ablates growth of Trop-2–expressing breast, colon, prostate cancers, but shows no evidence of systemic toxicity, paving the way for a paradigm shift in Trop-2–targeted therapy.
- 1 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from 3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability
Next-generation Trop-2–targeted therapy against advanced cancers is hampered by expression of Trop-2 in normal tissues. We discovered that Trop-2 undergoes proteolytic activation by ADAM10 in cancer cells, leading to the exposure of a previously inaccessible protein groove flanked by two N-glycosylation sites. We designed a recognition strategy for this region, to drive selective cancer vulnerability in patients. Most undiscriminating anti–Trop-2 mAbs recognize a single immunodominant epitope. Hence, we removed it by deletion mutagenesis. Cancer-specific, glycosylation-prone mAbs were selected by ELISA, bio-layer interferometry, flow cytometry, confocal microscopy for differential binding to cleaved/activated, wild-type and glycosylation site–mutagenized Trop-2. The resulting 2G10 mAb family binds Trop-2–expressing cancer cells, but not Trop-2 on normal cells. We humanized 2G10 by state-of-the-art complementarity determining region grafting/re-modeling, yielding Hu2G10. This antibody binds cancer-specific, cleaved/activated Trop-2 with Kd < 10−12 mol/L, and uncleaved/wtTrop-2 in normal cells with Kd 3.16×10−8 mol/L, thus promising an unprecedented therapeutic index in patients. In vivo, Hu2G10 ablates growth of Trop-2–expressing breast, colon, prostate cancers, but shows no evidence of systemic toxicity, paving the way for a paradigm shift in Trop-2–targeted therapy.